Eisai Co., Ltd. ESAIY
7.86 USD -0.03 (-0.38%)
Nov 4, 2026, 10:37 AM EST
7.85 Day range 7.86
5.69 52-week range 8.58
- YTD
- +6.50%
- 1 year
- +7.52%
- Market cap
- 8.87B
- EPS (ttm)
- 0.23
- P/E ratio
- 34.17
- YTD return
- +6.50%
- 1-year return
- +7.52%
- Volume
- 16.70K
- Avg volume
- 58.54K
- Open
- 7.85
- Previous close
- 7.89
- Day's range
- 7.85 – 7.86
- 52-week range
- 5.69 – 8.58
2Y -0.50 (-5.99%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 12, 2026 | Mar 31, 2026 | — | -0.0184 | — | — |
| Feb 4, 2026 | Dec 31, 2025 | — | 0.09889 | — | — |
| Nov 5, 2025 | Sep 30, 2025 | — | 0.06102 | — | — |
| Jul 30, 2025 | Jun 30, 2025 | 0.05949 | 0.08996 | +0.03 | +51.22% |
| May 12, 2025 | Mar 31, 2025 | — | 0.00536 | — | — |
| Feb 3, 2025 | Dec 31, 2024 | — | 0.00088 | — | — |
News
Eisai Co., Ltd. (ESAIY) Q1 2027 Earnings Call Transcript 
FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug 
Eisai Co., Ltd. (ESAIY) Analyst/Investor Day Transcript 
Eisai Co., Ltd. (ESAIY) Q4 2026 Earnings Call Transcript 
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study 
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated. 
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting 
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency 
Eisai Co., Ltd. (ESAIY) Q3 2026 Earnings Call Transcript 
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle
Your note
Sign in to keep a note on ESAIY — it syncs with the Stock Master app.